Results 181 to 190 of about 581,943 (291)

Comparison between [<sup>68</sup>Ga]Ga-FAPI-46 and [<sup>18</sup>F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer. [PDF]

open access: yesEJNMMI Res
Küper AT   +16 more
europepmc   +1 more source

Giving and receiving help in three contexts as predictors of alcohol outcomes in a longitudinal study of sober living house residents

open access: yesAmerican Journal of Community Psychology, EarlyView.
Abstract Although peer support is central to the social model approach emphasized in sober living houses (SLHs), no longitudinal studies have examined helping among SLH residents. This longitudinal study examined benefits of helping in three contexts among SLH residents. Data were from 205 participants entering 28 SLHs across 2021–2023. Interviews were
Sarah E. Zemore   +4 more
wiley   +1 more source

Implementation of Youth Empowerment Services (YES) juvenile justice diversion program: A first‐person account

open access: yesAmerican Journal of Community Psychology, EarlyView.
Abstract In Santa Barbara County, the Youth Empowerment Services (YES) Program brought together several government and community‐based organizations, as well as a university‐based evaluation team, to provide pre‐adjudication diversion to youth ages 12 to 17.
Angela Pollard   +7 more
wiley   +1 more source

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123. [PDF]

open access: yesNPJ Breast Cancer
Gouveia MC   +33 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo   +38 more
wiley   +1 more source

Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L. [PDF]

open access: yesESMO Open
Matsubara T   +20 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy